Intravenous Compared to Oral Busulfan with Cyclophophamide for Allogeneic Hematopoietic Progenitor Cell Transplant Conditioning for AML and MDS

被引：0
|
作者：
Sobecks, Ronald
Rybicki, Lisa [1 ]
Kalaycio, Matt
Dean, Robert
Andresen, Steven [1 ]
Pohlman, Brad
Bolwell, Brian J.
Copelan, Edward A.
机构：
[1] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1427 / 1428
页数：2
相关论文
共 50 条
  • [41] Effect of comorbidities on allogeneic hematopoietic stem cell transplant outcomes in AML/MDS patients in first complete remission
    Shahjahan, M
    Alamo, J
    de Lima, M
    Khouri, I
    Gajewski, J
    Andersson, B
    Champlin, R
    Giralt, SM
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2004, 10 (02) : 12 - 13
  • [42] HIGH DOSE ORAL BUSULFAN AND INTRAVENOUS MELPHALAN AS CONDITIONING THERAPY FOR AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) FOR THE TREATMENT OF PEDIATRIC SOLID TUMORS
    Seber, A.
    Ginani, V. C.
    Gouveia, R., V
    Zecchin, V. G.
    Barros, D. P.
    Ibanez, A.
    Marconcini, J.
    Villela, N.
    Felix, O. M. W. O.
    Simoes, P. C.
    Seixas, M. T.
    Lee, M. L. M.
    Lederman, H. M.
    Caran, E. M.
    Macedo, C. R.
    Petrilli, A. A.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (02) : S264 - S264
  • [43] Similar Risk of Relapse and Survival with Post-Transplant Cyclophosphamide Compared to Standard Gvhd Prophylaxis after Allogeneic Hematopoietic Cell Transplantation for AML and MDS
    Yasin, Hassaan
    Naqvi, Mahrukh
    Kim, Jongphil
    Faramand, Rawan
    Puglianini, Omar Alexis Castaneda
    Khimani, Farhad
    Lazaryan, Aleksandr
    Nishihori, Taiga
    Nieder, Michael
    Pidala, Joseph
    Bejanyan, Nelli
    BLOOD, 2022, 140 : 4886 - 4888
  • [44] Intravenous versus Oral Busulfan-Based Conditioning for Pediatric Allogeneic Hematopoietic Cell Transplantations: Did The Pendulum Swing Too Far, Too Fast?
    Bredeson, Christopher
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2013, 19 (12) : 1657 - 1658
  • [45] Gonadal Function after Busulfan Compared with Treosulfan in Children and Adolescents Undergoing Allogeneic Hematopoietic Stem Cell Transplant
    Faraci, Maura
    Diesch, Tamara
    Labopin, Myriam
    Dalissier, Arnaud
    Lankester, Arian
    Gennery, Andrew
    Sundin, Mikael
    Uckan-Cetinkaya, Duygu
    Bierings, Marc
    Peters, Anke M. J.
    Garwer, Martina
    Schulz, Ansgar
    Michel, Gerard
    Giorgiani, Giovanna
    Gruhn, Bernd
    Locatelli, Franco
    Giardino, Stefano
    Uyttebroeck, Anne
    Rialland, Fanny
    Itala-Remes, Maija
    Dreger, Peter
    Shaw, Peter J.
    Bordon, Victoria
    Schlegel, Paul G.
    Mellgren, Karin
    Moraleda, Jose M.
    Patrick, Katharine
    Schneider, Pascale
    Jubert, Charlotte
    Lawitschka, Anita
    Salooja, Nina
    Basak, Grzegorz W.
    Corbacioglu, Selim
    Duarte, Rafael
    Bader, Peter
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (09) : 1786 - 1791
  • [46] Efficacy comparison of oral versus intravenous busulfan in a BuCy conditioning regimen for allogeneic BMT
    Lee, Je-Hwan
    Choi, Seong-Jun
    Lee, Junl-Hee
    Seol, Miee
    Lee, Young-Shin
    Ryu, Seong-Gil
    Kang, Young-Ah
    Lee, Yoo-Hyung
    BLOOD, 2007, 110 (11) : 340B - 340B
  • [47] Reduced intensity conditioning (RIC) for allogeneic hematopoietic stem cell transplantation (HCT) in patients with AML evolved from MDS or therapy related AML
    O'Donnell, MR
    Roberto, R
    Stein, AS
    Palmer, J
    Slovak, M
    Nakamura, R
    Snyder, DS
    Chang, K
    Pullarkat, V
    Forman, SJ
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (02) : 41 - 41
  • [48] ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) FOR PATIENTS IN THE 6TH AND 7TH DECADES OF LIFE WITH AML OR MDS USING MYELOABLATIVE, REDUCED TOXICITY IV BUSULFAN/FLUDARABINE (BUFLU) CONDITIONING REGIMEN
    Alatrash, G.
    Andersson, B.
    Pelosini, M.
    Rondon, G.
    Qazilbash, M.
    Giralt, S.
    Silva, L. de Padua
    Hosing, C.
    Kebriaei, P.
    Zhang, W.
    Saliba, R.
    Champlin, R.
    de Lima, M.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (02) : 106 - 106
  • [49] Allogeneic Stem Cell Transplantation with Myeloablative Compared with Reduced-Intensity Conditioning for AML and Mds; 20 Years Later
    Shimoni, Avichai
    Yerushalmi, Ronit
    Shem-Tov, Noga
    Danylesko, Ivetta
    Avigdor, Abraham
    Nagler, Arnon
    BLOOD, 2023, 142
  • [50] Cyclophosphamide-Busulfan Instead of Busulfan-Cyclophosphamide for Conditioning in Allogeneic Hematopoietic Stem Cell Transplantation
    Cantoni, Nathan
    Gerull, Sabine
    Heim, Dominik
    Halter, Joerg
    Tsakiris, Dimitrios
    Bucher, Christoph
    Rovo, Alicia
    Arber, Caroline
    Buser, Andreas S.
    Passweg, Jakob R.
    Tichelli, Andre
    Stern, Martin
    Gratwohl, Alois
    BLOOD, 2009, 114 (22) : 894 - 894
12345